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Abstract
OBJECTIVES: Many adults with repaired tetralogy of Fallot will require a pulmonary valve replacement (PVR), but there is no consensus on
the best timing. In this study, we aim to evaluate the impact of age at PVR on outcomes.
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METHODS: This is a national multicentre retrospective study including all patients >15 years of age with repaired tetralogy of Fallot who
underwent their first PVR between 2000 and 2013. The optimal age cut-off was identified using Cox regression and classification and re-
gression tree analysis.
RESULTS: A total of 707 patients were included, median age 26 (15–72) years. The mortality rate at 10 years after PVR was 4.2%, and the se-
cond PVR rate of 6.8%. Age at PVR of 35 years was identified as the optimal cut-off in relation to late mortality. Patients above 35 years of
age had a 5.6 fold risk of death at 10 years compared with those with PVR under 35 years (10.4% vs 1.3%, P < 0.001), more concomitant tri-
cuspid valve repair/replacement (15.1% vs 5.7%, P < 0.001) and surgical arrhythmia treatment (18.4% vs 5.9%, P < 0.001). In those under
50 years, there was an 8.7 fold risk of late death compared with the general population, higher for those with PVR after 35 than those with
PVR below 35 years (hazard ratio 9.9 vs 7.4).
CONCLUSIONS: Patients above 35 years of age with repaired tetralogy of Fallot have significantly worse mortality after PVR, compared
with younger patients and a higher burden of mortality relative to the general population. This suggests that there are still cases where the
timing of initial PVR is not optimal, warranting a re-evaluation of criteria for intervention.




NCHDA National Congenital Heart Disease Audit
NICOR National Institute for Outcomes Research
PV Pulmonary valve
PVR Pulmonary valve replacement
RV Right ventricular
rTOF Repaired tetralogy of Fallot
ToF Tetralogy of Fallot
TVR Tricuspid valve repair/replacement
VSD Ventricular septal defect
INTRODUCTION
Tetralogy of Fallot (ToF) is the most common type of cyanotic con-
genital heart disease and outcomes of surgical intervention have
improved. Many centres have recently reported procedural mortal-
ity of <3% [1, 2]. Adults with repaired ToF (rToF) represent an
increasing population, with steadily improving long-term survival.
The main challenge in managing these patients is the progres-
sive right ventricular (RV) dilation and dysfunction due at least in
part to pulmonary valve (PV) regurgitation and/or residual ob-
struction leading to heart failure, arrhythmias or sudden cardiac
death. Severe pulmonary regurgitation will be present in 40–80%
of patients at 5–10 years after correction; while at 35 years of fol-
low-up, 40% will have undergone PV replacement (PVR) [1].
PVR was associated with improved RV volumes, improved left
ventricular function, reduced tricuspid regurgitation and
improved functional status [3–5]. There are no studies comparing
the late outcomes of medically managed residual pulmonary
lesions versus early PVR in these patients. A propensity-matched
cohort from the INDICATOR registry showed no advantage in
adverse effects in the group undergoing PVR, although with the
limitations of retrospective matching [6]. In a recent small non-
controlled trial, PVR was associated with fewer adverse events in
an asymptomatic population with moderate PV regurgitation [7].
The question of long-term benefits, or harms, with PVR in rToF
and the timing, early versus delayed, is still open to debate.
Given the length of follow-up likely to be necessary and that
most congenital cardiologists favour PVR using conventional cri-
teria, a randomized controlled trial is unlikely [8].
The timing of PVR in rToF is not well established, being depend-
ent on symptoms, degree of pulmonary regurgitation/residual
stenosis, RV volume/function or the presence of arrhythmias [9].
Current guidelines offer strong recommendations when the conse-
quences of RV volume/pressure overload are evident (either
symptoms or RV dilation), but do not address the area of long-
term right and left ventricular preservation or risk of sudden death
[9, 10]. Our understanding of the underlying mechanisms of pro-
gression of RV dysfunction in the presence of PV regurgitation,
which is generally well-tolerated through childhood is currently
lacking. This could translate into PVR being performed in some
patients when irreversible changes have already occurred. At the
moment, relying on RV volumes as a threshold for intervention in
asymptomatic patients could be an oversimplification of a very
complex biological mechanism; whilst waiting for the first symp-
toms to appear might offer too little, too late [8].
A recent analysis from the INDICATOR cohort identified age at
PVR over 28 years as a predictor of worse outcomes in rToF in
addition to RV hypertrophy and/or dysfunction [11]. PVR before
the age of 17.5 years was previously shown to be beneficial in
terms of cardiopulmonary exercise test performance in rToF [12].
Patients surviving without a PVR until the age of 35 were consid-
ered to have a favourable phenotype in a study by Frigiola et al.
[13] Even though there were few cases with significant residual
regurgitation or stenosis among them, many still had evidence of
subclinical RV dysfunction. With ToF operation nowadays occur-
ring early in life, the patient’s age has become a surrogate for the
length of exposure to any residual lesions that might have been
left. We aim to use data from the UK National Congenital Heart
Disease Audit (NCHDA) to evaluate the impact of age at PVR on
long-term outcomes and identify a possible age cut-off where
these outcomes significantly change.
PATIENTS AND METHODS
Ethical statement
The National Institute for Outcomes Research (NICOR) holds ap-
proval to use patient data for research purposes. The data re-
quest for this manuscript was processed and approved in January
2015 by the NICOR Research Board. The need for patient-level
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consent to participate in this retrospective study with anony-
mized data was waived by the NICOR Research Board.
The data set
The NCHDA was set up in 2000 to assess outcomes after con-
genital cardiovascular procedures in the UK. Data submission is
mandatory for all UK centres performing these procedures.
Diagnosis and procedure coding is according to the European
Paediatric Cardiac Code Short List and centres have a yearly ex-
ternal data validation visit. Linkage with the Office of National
Statistics ensures updated life status in England. The NCHDA is
run under the auspices of the NICOR.
Patient selection
All data on 5616 patients with ToF operated between January
2000 and March 2013 were selected and anonymized. From
these, all patients undergoing a surgical PVR procedure were
selected, resulting in 1102 entries. To ensure maximum accuracy
on life status, patients from Scotland, Northern Ireland and over-
seas were excluded (n = 162) as there is no linkage with the Office
of National Statistics. Also excluded in consecutive order were:
patients where the review of the diagnoses codes revealed com-
plex ToF variants or associated defects such as pulmonary atresia,
major aorto-pulmonary collaterals, double outlet right ventricle,
atrioventricular septal defect, absent PV, non-confluent pulmon-
ary arteries, isomerism, other vascular anomalies (n = 77); age at
PVR <15 years (n = 138); documented redo PVR (n = 7); ToF repair
in the same procedure (n = 11). This resulted in 707 patients with
rToF above 15 years of age, undergoing the first PVR between
2000 and 2013 in England and Wales. The age limit of 15 years
was chosen empirically to exclude children, where the indication
for PVR might differ significantly in favour of residual obstruction,
and also match the methodology of 5-year age increments.
Statistical analysis
Frequencies are given as numbers and percentages, continuous
values as median (interquartile range). Population characteristics
were compared using the Mann–Whitney U-test, Kruskall–Wallis
test and Fisher’s exact test.
Early outcomes are described based on known status at 30 days
post-procedure. Late outcomes are estimated using the Kaplan–
Meier method and reported as percentage and 95% confidence
intervals. In order to identify an age cut-off impacting outcomes,
the patients were stratified into 8 age brackets: from 15 to 50 years
in increments of 5 years, and 1 group with all patients >50 years
old, each bracket including the upper interval limit age, but not
the lower interval limit age values. The hazard ratio (HR) for each
age bracket was calculated relative to the baseline bracket (15–
20 years) using a Cox regression stratified by centre and single age
cut-offs corresponding to the highest increase in HR were selected
for evaluation, and the proportionality assumption tested using
Schoenfeld residuals. Log-likelihood was used as a correlative
measure for determining the optimal cutpoint [14]. Classification
and Regression Tree Analysis (CART) was used as an alternative
method for automatic identification of optimal cut-offs and the
results from both approaches were compared [15].
Late mortality was also compared to that of the matched general
UK population, using a methodology described before [16]. Statistical
analyses were done with STATA/SE 16 (StataCorp LP, College Station,
TX, USA) and R version 3.6 (R Development Core Team).
RESULTS
A total of 707 rTOF patients were included (54.5% male) from 14
centres (median 48/centre, 4–140 patients/centre). The median
Table 1: Demographic, clinical and procedural characteris-
tics of patients with repaired ToF undergoing PVR (n = 707)
Age (years), median (IQR) 26.4 (20.5–37.6)









Male gender, n (%) 385 (54.5)
Genetic condition, n (%) 36 (5.1)
Concomitant procedures, n (%)
Pulmonary arterioplasty 153 (21.6)
Tricuspid valve repair/replacement 60 (8.5)
Repair/annuloplasty 58 (8.2)
Replacement 2 (0.3)
Residual septal defect repair 18 (2.6)
Surgical arrhythmia treatment 68 (9.6)
Maze operation/atrial fibrillation ablation 61 (8.6)
Ventricular ablation 7 (1)
Epicardial pacemaker 4 (0.5)
Bypass time min (median, IQR) 87 (66–116)
Cross-clamp time (min), median (IQR) 52 (38–70)




Follow-up (years), median (IQR) 3.5 (1.8–5.6)
IQR: interquartile range; PVR: pulmonary valve replacement; ToF: tetralogy
of Fallot.
Figure 1: Age at pulmonary valve replacement (PVR) distribution showing the
number of patients for each 2-year age increment. The majority of patients
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age was 26.4 years (interquartile range 20.5–37.6 years, youngest
15, oldest 72.5 years). Table 1 shows the general patients’ charac-
teristics in the whole group. Most patients were under 40 years
old (Fig. 1).
The 30-day mortality and second PVR rates were 1% and 0.4%
respectively. Survival was 98.1% (96.8–98.9) at 1 year after PVR,
96.8% (94.9–98.1) at 5 years and 95.8% (93.2–97.5) at 10 years.
Freedom from PVR was 99.4% (98.5–99.8) at 1 year, 97.7% (95.8–
98.7) at 5 years and 93.2% (83.6–97.3) at 10 years. Of the 14
patients undergoing the second PVR during our study follow-
period, just 1 died.
Older age at pulmonary valve replacement is
associated with worse survival
When evaluating the differences in survival by age brackets, it
was found that the age brackets of 35–40, 40–45 and >50 were
associated with increased mortality risk compared to the baseline
bracket of 15–20, with P-values <0.1 (Table 2).
Based on these findings, we tested several age cut-offs (ranging
from 30 to 50 years) for the goodness of fit in a Cox regression
modelling survival, stratified by the hospital (Table 3). An age
cut-off of 35 years was found to be the optimal one, with the
highest log-likelihood. CART analysis identified a cut-off at
35 years and a second one at 62 years, but the latter resulting
group had only 11 patients and was discarded. As such, both
methods identified the same age cut-off point.
Pulmonary valve replacement after 35 years is
associated with worse outcomes
There were 495 patients undergoing PVR before 35 years of age
and 212 after. Patients with rToF undergoing PVR after 35 years
had significantly higher mortality at 10 years than those under-
going PVR before 35 years (10.4% vs 1.3%, P < 0.001, Fig. 2), but
similar incidence for second PVR at 10 years (3.4% vs 7.3%,
P = 0.4). Of the patients undergoing PVR before the age of 35, 61
patients were now aged over 35 and none had died.
Patients older than 35 had fewer genetic syndromes (0.9% vs
6.9%, P = 0.001), more concomitant tricuspid valve repair/replace-
ment (TVR) procedures (15.1% vs 5.7%, P < 0.001), more concomi-
tant surgical arrhythmia treatment (18.4% vs 5.9%, P < 0.001) and
more concomitant residual ventricular septal defect (VSD) closures
(4.3% vs 1.8%, P = 0.06). There were no significant differences in
gender (P = 0.6), concomitant pulmonary arterioplasty (P = 0.9), op-
eration era (P = 0.5) or follow-up length (P = 0.8).
The significant increase in mortality at 10 years for those under-
going PVR after 35 years was maintained when patients with con-
comitant TVR were excluded (HR 4.1, P = 0.02) and when those
with surgical arrhythmia treatment were excluded (HR 5.3,
P = 0.001). In addition, concomitant TVR was associated with fur-
ther significantly increased 10-year mortality in patients with PVR
after 35 years (HR 4.9, P = 0.03), but not in those with PVR under
35 years (HR 3.5, P = 0.3). Concomitant surgical arrhythmia treat-
ment or residual VSD closure did not influence 10-year mortality
overall or in either group (P > 0.5 for all log-rank tests).
Comparison of survival after pulmonary valve
replacement and the general population
Patients with rToF undergoing PVR had a 6.6 times higher risk
of death at 10 years after PVR compared to the general popula-
tion in the UK (HR 6.6, P < 0.001), with a mortality excess of
3.1% (1.4–5.6%). The relative risk was exacerbated in patients
under 50 (HR 8.7, P < 0.001) and reduced in those over 50 years
(HR 3.6, P = 0.01), likely confounded by the increased preva-
lence of other causes of death in the general population after
this age.






95% CI P-value Log
likelihood
30 4.7 1.7–13.1 0.003 -70.2
35 5.6 2.1–14.9 <0.001 -68.5
40 3.5 1.4–8.9 0.007 -72
45 2.2 0.8–6.3 0.1 -74.3
50 3.4 1–11.1 0.04 -73.6
Values are from univariable Cox regression stratified by centre.
CI: confidence interval.
Table 2: Relative mortality risk after PVR at different age
brackets
Age bracket (years) Hazard ratio 95% CI P-value
15–20 Baseline Baseline Baseline
20–25 0.8 0.1–5.9 0.8
25–30 0.6 0.06–7.4 0.7
30–35 1 0.09–11.4 0.9
35–40 4.8 0.9–25.7 0.07
40–45 6.4 1.1–37 0.04
45–50 1.8 0.2–20.4 0.6
>50 5.6 0.9–33.2 0.06
HR values from univariable Cox regression, stratified by centre.
CI: confidence interval; PVR: pulmonary valve replacement.
Figure 2: Kaplan–Meier analysis of mortality at 10 years stratified by age over
and under 35 years at PVR in all 707 patients with repaired tetralogy of Fallot
undergoing PVR. Patients undergoing PVR over 35 years of age have signifi-
cantly higher mortality at 10 years. PVR: pulmonary valve replacement.
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Patients aged 35–50 undergoing PVR had a higher risk of death
at 10 years than that of the matched general population, com-
pared to those undergoing PVR before 35 years (HR 9.9 vs 7.4)
and a higher mortality excess of 7.7% (3.2–15.3%) versus 0.9%
(0.2–2.6%), as shown in Fig. 3A and B
DISCUSSION
In a national cohort of 707 patients with rTOF undergoing the
first time PVR, age at surgery of >35 years was found to be associ-
ated with increased mortality at 10 years. This suggests that cur-
rent guidelines likely fail to adjust for subclinical changes that
might appear in long exposures to RV pressure or volume over-
load. The higher prevalence of concomitant TVR and surgical ar-
rhythmia treatment in these older patients further shows that
complications of RV dysfunction are more common with age,
and might negatively influence outcomes.
This is supported by the findings of the INDICATOR registry,
reporting a cut-off of 28 years for any of the primary endpoints
of mortality, aborted sudden death and sustained ventricular
tachycardia. In addition to age, the authors found that RV
hypertrophy or dysfunction, rather than dilation alone were
associated with worse ventricular arrhythmia free survival. Left
ventricular dilation/dysfunction and tricuspid regurgitation
were associated with arrhythmias and heart failure [11]. The
fact that there might be a subgroup of patients where current
guidelines for intervention, largely based on either symptoms
or RV size, lead to unsatisfactory outcomes is worrying and
should prompt a reevaluation. On the other hand, finding an
age cut-off, be it in 2 large studies, does not encourage indis-
criminate early PVR, but rather a search for better criteria for
intervention, which might reside in more sensitive systolic
function measurements. Until new criteria are established,
older age could be added in the individual decision algorithm
for PVR in repaired ToF.
These findings advise caution when deciding the timing of PVR
in rToF after the third decade of life, both in terms of postponing
an intervention in some patients, but also performing one in the
presence of irreversible RV dysfunction.
Our study is retrospective and lacks a comparative group of
patients treated conservatively. Consequently, we were unable to
differentiate between the effects of the natural history of rToF in
older ages and the effects of PVR. There are indirect clues that in
fact there is a component related directly to the age at PVR and
the procedural indication: none of the 61 patients followed past
the threshold of 35 years with a PVR done beforehand died in
the long term; the relative difference compared to the general
population was smaller in the younger group. We can speculate
that 2 populations could be identified in future studies: patients
with phenotypes negating the expected success of a PVR, such as
too severely dilated RVs, and patients with no obvious symptoms,
below the threshold for significant RV dilation, but with subclin-
ical RV dysfunction limiting the RV recovery post PVR.
The age at first PVR, cardiac function and clinical status seem
to be dependent on each other, and as such, older age should
not be the only reason for intervention, but rather a threshold
for closer follow-up and evaluation. There are data from the
INDICATOR study to suggest that when PVR was indicated out-
side the post hoc consensus criteria, there was an excess of ad-
verse effects compared to the medically treated group [6]. On the
other hand, data from a large UK study identifying the phenotype
of the patients free of PVR by age 35 showed that although most
have normal exercise tolerance and just mildly dilated RVs, they
did have decreased longitudinal RV systolic function, suggesting
subclinical dysfunction [13]. Currently, the American Heart
Association/American College of Cardiology guidelines recom-
mend follow-up visits guided by the physiological stage severity
of symptoms [9], while the European Society of Cardiology gives
only broad recommendations, for the follow-up to be individual-
ized [10]. A more sensible approach would be for age to augment
the clinical decision, with more frequent patient visits and more
detailed investigations targeted towards older patients, such as
magnetic resonance imaging to identify fibrosis [17, 18].
Although the emphasis traditionally has been on the impact of
TOF on the right ventricle, recent studies have also shown an im-
pact of rTOF on left ventricle (LV) function, including at early
follow-up. Clinically well children were found to have reduced
LV contractile reserve on exercise testing [19]. In adults, strain


































0 2 4 6 8 10
Follow-up (years)
A B
Figure 3: Comparison between Kaplan–Meier survival estimates of repaired tetralogy of Fallot patients undergoing pulmonary valve replacement (PVR) under 35 years
of age (A) and between 35 and 50 years of age (B) and simulated patients based on ONS matched population. Both the relative risk increase (HR 9.9 vs 7.4) and the ab-
solute mortality excess to the general population (7.7% vs 0.9%) were higher in those undergoing PVR between 35 and 50 years of age. CI: confidence interval; HR: haz-
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abnormal myocardial deformation was associated with cardio-
vascular events [20, 21]. PVR did not only result in a normaliza-
tion of RV volumes and function, but it also resulted in improved
LV filling and function and this effect was more pronounced at a
younger age [12].
The main concern surrounding the timing of PVR is that if per-
formed early it will lead to increased risks related to future redo
PVRs. Currently, reported rates of redo-PVR at 10 years in these
patients range from 26% to 11% [1], while a meta-analysis
reported 5-year redo rates from 0% to 12.1% [4]. Few studies
have the needed follow-up and patient numbers to report accur-
ate data in this area. In our study including 14 centres from
England and Wales, with 707 unselected patients undergoing
PVR, we found a 93.2% freedom from redo-PVR at 10 years, bet-
ter than the figures previously reported, in the context of newer
generation prosthesis and relatively short follow-up time. Redo
PVR can be associated with significant risks [22], but transcatheter
valve-in-valve implantation holds much promise for the future
[23]. In our study, of the 14 patients undergoing redo-PVR, 1 died
during follow-up.
It was worrying to observe that in the subgroup of patients
with rToF undergoing PVR, the relative risk of death compared to
the general population was very high, ranging from 3.6 to 8.7,
depending on the age group. In individuals with rToF undergoing
PVR under 50 years of age, we found an 8.7 relative risk of death
compared to the general population, while a previous study
reported a 4 times relative risk in a group of rToF, with or with-
out PVR [13]. Khairy et al. [24], showed a high prevalence of both
atrial and ventricular arrhythmias in rToF, 20.1% and 14.6% re-
spectively, markedly increased over the age of 45. In addition,
the main predictor for both types of arrhythmias was left ven-
tricular dysfunction, which is a marker of long-lasting cardiac
dysfunction These figures are worrying, as they could signal that
our current recommendations for intervention and follow-up are
not appropriate, that patients requiring PVR are at much higher
risk than previously considered and that PVR does not signifi-
cantly impact survival or even all of the above. Since a random-
ized trial comparing medical and surgical intervention in this
scenario is not possible (cardiologists are generally not in equi-
poise and favour PVR as well as the long-term follow-up
required), with proven advantages of PVR to cardiac function
and symptoms, surrogate methodologies need to be used to
evaluate each of the possible hypotheses leading to these find-
ings. Another area of improvement might be the initial repair,
with a target of minimal residual lesions, but in the end, that
might not be possible in some cases.
Limitations
This is a retrospective study and shares all the limitations of such
a study design. Being a procedure-based registry, limited clinical
data were collected, and no inferences could be made on the in-
dication for PVR, outside of the assumption that current guide-
lines were followed locally. The age cut-off could only be
adjusted by centre variation, and not by clinical or imaging data,
thus limiting the accuracy of the model. Cases, where interven-
tion was performed in more severe clinical scenarios, could not
be identified but were probably present based on the prevalence
of surgical treatment of complications. There was no medically
treated group to be used as a control, and due to current practi-
ces, a true comparator group might not be feasible, with
selection bias being unavoidable. Longer follow-up was not avail-
able due to changes in data sharing across the UK shortly after
the study was started.
CONCLUSIONS
Patients with rTOF aged 35 or more had significantly higher late
mortality, more concomitant surgical arrhythmia treatment and
tricuspid valve surgical procedures compared to younger
patients. There is high excess mortality compared to the general
population, higher when PVR is performed after 35 years. This
suggests that there are still a significant number of patients for
whom the timing or indication for PVR is not optimal, either
through diminishing returns in patients with severely dilated RVs
or already present complications, late intervention in the pres-
ence of subclinical RV dysfunction or both. These results do not
encourage indiscriminate early PVR, but rather closer follow-up
of patients with repaired ToF in the third decade of life, aimed at
ventricular function rather than size, and possibly support intro-
ducing age as an additional variable in the individual decision to
perform PVR. Further studies are needed to evaluate the subtle
changes in RV function with age and type of residual lesion, as
well as to investigate the long-term benefits of PVR in this group.
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